checkAd

     114  0 Kommentare Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

    BURNABY, British Columbia, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will participate in the following virtual investor conferences:

    • William Blair Biotech Focus Conference 2020 | Panel 4: New Therapies Impacting the Epilepsy Treatment Landscape on Thursday, August 6, 2020 at 12:00 pm ET
       
    • 2020 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2020 at 3:30 pm ET

    The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon's website at www.xenon-pharma.com. All webcasts will be posted for replay following the event for 30 days.

    About Xenon Pharmaceuticals Inc.

    We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

    “Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

    Investor/Media Contact:
    Jodi Regts
    Xenon Pharmaceuticals Inc.
    Phone: 604.484.3353
    Email: investors@xenon-pharma.com





    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences BURNABY, British Columbia, Aug. 04, 2020 (GLOBE NEWSWIRE) - Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will participate in the …

    Schreibe Deinen Kommentar

    Disclaimer